Abstract:At our hospital, MCA aneurysms are being treated with endovascular techniques, but in a minority of patients. Despite the rate of residual neck remnants, few retreatments were necessary and few rehemorrhages occurred. The periprocedural complication rate was not insignificant; therefore, in more recent years and at present, most MCA aneurysms are considered for clipping first at our center.
“…30 , an emerging endosaccular device and reported complete occlusion in 26.7% and a neck remnant in 56.7% of aneurysms at a median of 6-month followup. Use of these novel endoluminal and endosaccular devices requires dual-antiplatelet therapy to prevent thromboembolic events.…”
MCA aneurysm rupture with concomitant large intraparenchymal or sylvian fissure hematoma formation carries a grave prognosis. Simultaneous hematoma evacuation and aneurysm clipping with or without craniectomy can be an effective treatment modality.
“…30 , an emerging endosaccular device and reported complete occlusion in 26.7% and a neck remnant in 56.7% of aneurysms at a median of 6-month followup. Use of these novel endoluminal and endosaccular devices requires dual-antiplatelet therapy to prevent thromboembolic events.…”
MCA aneurysm rupture with concomitant large intraparenchymal or sylvian fissure hematoma formation carries a grave prognosis. Simultaneous hematoma evacuation and aneurysm clipping with or without craniectomy can be an effective treatment modality.
“…Many authors feel that surgical clipping offers select patients with ruptured MCA aneurysms the best long-term clinical outcome [32, 40–43]. …”
Section: Discussionmentioning
confidence: 99%
“…The Kuopio Cerebral Aneurysm Database found [3–6] that 29% of ruptured MBIF aneurysms presented with preoperative hydrocephalus. Abla et al [32] found that 24.2% of patients presented with hydrocephalus. Obstructive hydrocephalus in the setting of aSAH obviates the need for an external ventricular drain (EVD) which increases the risk of dual antiplatelet therapy.…”
Section: Discussionmentioning
confidence: 99%
“…More recently, Abla et al performed a retrospective review of all MCA aneurysms treated at single-intuition over a 5-year period [32]. Of the 149 MCA aneurysms included, surgical clipping was found to be the preferred method of treatment in 115 (77.2%) of cases.…”
Section: Retrospective Case Seriesmentioning
confidence: 99%
“…Of the 149 MCA aneurysms included, surgical clipping was found to be the preferred method of treatment in 115 (77.2%) of cases. Of the remaining MCA aneurysms 22.8% were treated via endovascular techniques, 76.5% of which were MBIF aneurysms [32]. …”
Middle cerebral artery (MCA) aneurysms are common entities, and those of the bifurcation are the most frequently encountered sublocation of MCA aneurysm. MCA bifurcation (MBIF) aneurysms commonly present with subarachnoid hemorrhage (SAH), are devastating, and are often lethal. At the present time, the treatment of ruptured MBIF aneurysms entails either endovascular or open microneurosurgical methods to permanently secure the aneurysm(s). The purpose of this report is to review the current available data regarding the relative superiority of endovascular versus open microneurosurgical clipping for the treatment of ruptured middle cerebral artery bifurcation aneurysms.
Although this study has its inherent limitations, the effect brought about by microsurgical clipping of MCA ANs remains superior to that of endovascular embolisation and it should be sustained as the first treatment choice. The decision about the treatment strategy should be made by a multi-disciplinary team consisting of specialists from both teams, bearing in mind the higher occlusion rate and longevity of the surgical treatment.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.